Related content

Reply to Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?

By Maru Dipen M.   Agarwal Atin A.   Hu Chung-Yuan   Chang George J.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1282-1282

Blackwell Publishing

Access to resources Recommend Favorite

Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?

By You Kai Yun   Gao Yuan Hong  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1281-1282

Blackwell Publishing

Access to resources Recommend Favorite

Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare data, 1998-2007

By Haynes Alex B.   You Y. Nancy   Hu Chung-Yuan   Eng Cathy   Kopetz E. Scott   Rodriguez-Bigas Miguel A.   Skibber John M.   Cantor Scott B.   Chang George J.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1162-1170

Blackwell Publishing

Access to resources Recommend Favorite

Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapy

By Zaki Bassem I.   Suriawinata Arief A.   Eastman Alan R.   Garner Kristen M.   Bakhoum Samuel F.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1733-1742

Blackwell Publishing

Access to resources Recommend Favorite

Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation

By Gordon Michael A   Gil Ji   Lu Bo   Zhang Wu   Yang Dongyun   Yun Jim   Schneider Sylke   Groshen Susan   Iqbal Syma   Press Oliver A   Rhodes Katrin   Lenz Heinz-Josef  

Pharmacogenomics, Vol. 7, Iss. 1, 2006-01 ,pp. : 67-88

Future Medicine

Access to resources Recommend Favorite